Beyond The Numbers: 15 Analysts Discuss Legend Biotech Stock
Portfolio Pulse from Benzinga Insights
Over the past three months, 15 analysts have shared their insights on Legend Biotech (NASDAQ:LEGN), with the majority expressing bullish sentiments. The average 12-month price target is $76.73, with a high of $90.00 and a low of $60.00. Recent analyst actions include maintaining, raising, and lowering ratings and price targets. Legend Biotech has shown significant revenue growth but faces challenges in profitability and financial performance.
August 12, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Legend Biotech (NASDAQ:LEGN) has received predominantly bullish ratings from analysts over the past three months. The average 12-month price target is $76.73, with a high of $90.00 and a low of $60.00. Recent analyst actions include maintaining, raising, and lowering ratings and price targets. The company has shown significant revenue growth but faces challenges in profitability and financial performance.
The majority of analysts have expressed bullish sentiments towards Legend Biotech, with a high average price target. This positive outlook is likely to boost investor confidence in the short term. However, the company's challenges in profitability and financial performance may temper some of the enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100